A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer
Completed
Innocrin Pharmaceutical
Phase 2
The goal of this clinical study is to determine the safety, tolerability, pharmacokinetics
and activity of Seviteronel, a lyase-selective inhibitor of CYP17, in patients with
castration-resistant prostate cancer (CRPC).
Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer
Completed
National Cancer Institute (NCI)
Phase 2
The goal of this clinical study is to determine the safety and efficacy of VT-464, a
lyase-selective inhibitor of CYP17, in patients with castration-resistant prostate cancer
(CRPC) who have been previously treated with Enzalutamide, Androgen Receptor Positive
Triple-Negative Breast Cancer Patients, and Men with ER positive Breast Cancer.
Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer
Completed
Innocrin Pharmaceutical
Phase 2
The goal of this clinical study is to determine the safety and efficacy of VT-464, a
lyase-selective inhibitor of CYP17, in patients with castration-resistant prostate cancer
(CRPC) who have been previously treated with Enzalutamide, Androgen Receptor Positive
Triple-Negative Breast Cancer Patients, and Men with ER positive Breast Cancer.
Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.
Completed
Prostate Cancer Clinical Trials Consortium
Phase 2
The goal of this clinical study is to determine the efficacy and safety of Seviteronel, a
lyase-selective inhibitor of CYP17 and an androgen receptor antagonist, in patients with
castration-resistant prostate cancer (CRPC) who have been previously treated with
enzalutamide and/or abiraterone.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.